

Special Issue

Cell Therapy in Solid Cancers: Current and Future Landscape

Message from the Guest Editors

Leveraging the immune system to treat cancer is now a reality with broad applications across oncology. Using novel designer molecules to pharmacologically target immune checkpoints and recruit the host's innate immune effectors directly to the tumor cells has been the main modality so far. This approach achieved long-term remission in a small subset of cancer patients but requires regular administration, and many others will invariably progress. As such, the idea of introducing manipulated cancer-targeting immune cells into a patient as a "living cure" is highly attractive.

Modified cell therapy, such as CAR-T, is now a standard in several hematologic malignancies and holds great promise in solid tumors. The evolving field demands innovative solutions, including developing "off-the-shelf" anti-cancer cell products, the role of non-T-cells such as NK cells and macrophages, appropriate conditioning regimen, and management of long-term toxicities in survivors.

Guest Editors

Dr. Wenwee Ma
Prof. Dr. Jan Joseph Melenhorst
Dr. Li Yin

Deadline for manuscript submissions

closed (30 November 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/204205

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)